期刊
MATERIALS TODAY CHEMISTRY
卷 17, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.mtchem.2020.100303
关键词
Anti-inflammation; Anti-thrombosis; Phosphatidylserine exposure; Hemocompatible surface; Rapid endothelialization
资金
- National Key Research and Development Program of China [2016YFC1100402]
- National Natural Science Foundation of China [51973222, 21807097, 51573186]
- National Natural Science Foundation of Jilin Province of China [20180101178JC, 20190701030GH]
Reduction of inflammation and thrombosis caused by implanted devices is critical for clinical success. To this end, the strategy based on programmable release of anti-inflammatory and anti-thrombotic agents from the widely-used polycaprolactone (PCL)/gelatin nanofiber scaffold is developed. The release of 2-O-D-Glucopyranosyl-t-ascorbic Acid (AA-2G) and heparin are controlled by reactive oxygen species (ROS)-responsive poly(ethylene glycol)-based beta-thioether ester copolymer (PEGDA-EDT) and mesoporous silica nanoparticles (MSN) in the nanofiber, respectively. The in vitro assay demonstrate that the scaffolds are hemocompatible with the resistance of platelet adhesion; the control release of AA-2G prevents initial inflammation and oxidation of the blood cells, and the subsequent release of heparin entitles nanofibers with long-term anti-thrombotic capability. In addition, rapid endothelialization is obtained on the surface of nanofiber scaffolds for the further enhancement of the hemocompatibility. In vivo implant evaluation convinces that the nanofiber scaffolds possess high biocompatibility with the substantial resistance for inflammation and thrombosis. Hence, our work paves a new way to develop the anti-inflammatory and anti-thrombotic tissue-engineering substrates through programmable delivery of two or multiple drugs. (C) 2020 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据